Pupil Assessment for CAR-T Neurotoxicity
This study is looking at whether changes in your pupil size and how they react to light can help predict neurological side effects (neurotoxicity) after you receive CAR-T cell therapy. Researchers will use a special handheld device called the NeurOptics® NPi®-300 Pupillometer to measure your pupils. This device is placed in front of your eyes and is non-invasive. The study aims to see if a drop in your NPi (Neurological Pupil index) score after CAR-T infusion is linked to neurotoxicity. They also want to see if a big difference in NPi between your two eyes is related to how severe any symptoms are. This study is open to adults aged 18 and older who are receiving CAR-T cell therapy. The study is currently unclear on its recruitment status.
- Study design
- This is an observational study, meaning researchers will monitor participants without assigning specific treatments. It plans to enroll 100 participants.
- What's involved
- The study involves measurements with the NeurOptics® NPi®-300 Pupillometer. The primary endpoint is measured through study completion, which is an average of 1 year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ranjit Nair, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Through study completion; an average of 1 year.